Table 1. Summary of Key Epidemiologic Inputs of Effectiveness.
Author,Year | InitialPrevalenceof LTBI | AnnualReactivation rate | TSTSensitivity | TST Specificity- NO BCG | TST Specificity-BCG | IGRASensitivity | IGRASpecificity | LTBI Completionrate | Efficacy of Full LTBI regimen | Probability of adverse event |
Burgos, 2009 | 58% | 1.10% | NA | NA | NA | 95% | 98% | 80% | 69% | 18% |
de Perio, 2009 | 5% | 0.02% | 67% | 98% | 70% | 76% | 96% | 31% | 90% | 0.60% |
Deuffic-Burban, 2010 | 41% | 0.24% | 73% | NA | 60% | 76% | 96% | 57% | 69% | 0.001% |
Diel, 2007 | 11% | 0.30% | 90% | NA | 61% | 90% | 100% | 100% | 80% | 0% |
Diel, 2007 | 28% | 0.30% | 93% | NA | 25% | 95% | 100% | 100% | 80% | 0% |
Kowada, 2010 | 5% | 0.28% | 80% | 97% | 59% | 84% | 99% | 80% | 70% | 0.30% |
Kowada, 2010 | 36% | 0.15% | NA | NA | NA | 81% | 99% | 80% | 70% | 0.30% |
Kowada, 2008 | 20% | 0.28% | 71% | 98% | 15% | 76% | 96% | 90% | 70% | 1.30% |
Linas, 2011 (adult close contacts) | 43.7% | 1.02% | 89% | 98% | NA | 83% | 99% | 48% | 90% | 1% |
Linas, 2011(recent adult immigrants to US) | 41.4% | 0.08% | 89% | NA | 92% | 83% | 99% | 51% | 90% | 1% |
Marra, 2008 | 21% | 0.41% | 99% | 95% | 36% | 99% | 96% | 28% | 90% | 0.30% |
Oxlade, 2007 | 35% | 0.10% | 95% | 98% | 60% | 95% | 98% | 21% | 80% | 1% |
Pareek, 2011 | 23% | 0.25% | NA | NA | NA | 84% | 99% | 81% | 65% | 0.20% |
Pooran, 2010 | 30% | 1.25% | 85 | 80%* | NA | 95%/89%** | 100%/95%** | 72% | 65% | 0.3% |